Mathematical modelling of fungal growth *in vitro*


Joshua Sia

Supervisors: Dr Reiko Tanaka, Tara Hameed

June 2021

Invasive Aspergillosis

- Invasive Aspergillosis (IA) is a pulmonary disease
- Caused by Aspergillus fungi, mainly A. fumigatus
- IA has a **high mortality rate** in neutropenic individuals (86%) [1]



Lung tissue of a patient with IA [2]

Current treatments

- Anti-fungal drugs (Voriconazole, Itraconazole, etc.)
- High rate of treatment failure about 75-85% [3][4][5]
- Up to 31% of patients have discontinued anti-fungal therapies due to drug-related adverse effects such as toxicity (n = 201) [6]
- We need to understand fungal growth better to design future treatment strategies!


Background

- Araujo et al. (2004): Comparison of germination rates for three Aspergillus species [7], Paisley et al. (2005): Correlation between virulence and fungal growth rates across nine A. fumigatus isolates [8]
- No previous studies conducted which compare growth rates based on hyphal length across multiple Aspergillus strains
- Richard et al. (2018): Epithelial cells (ECs) inhibit A. fumigatus conidia germination
- Effect of ECs on hyphal growth remains unknown


Aims and Objectives


- Aim
 - Investigate why *A. fumigatus* is the most prevalent species in IA by using the hyphal growth rate as a virulence factor
- Objectives
 - Propose fundamental mathematical models of Aspergillus hyphal growth and perform model selection
 - Compare the growth rates of A. fumigatus growth with and without epithelial cells
 - Compare the growth rates of multiple Aspergillus strains and species

Growth of 11 Aspergillus strains



A. fumigatus growth with and without ECs





Workflow

Data

- Multiple species
- Epithelial cells

Model

- Exponential and logistic models
- Complete and partial pooling models

Evaluation

- AIC
- BIC
- Cross validation

Growth models

ECs dataset

Exponential model

$$\hat{y}(x) = A e^{Bx} \quad (1)$$

A: Intercept

B: Growth rate

MS dataset

Logistic model

$$\hat{y}(x) = \frac{A}{1 + e^{\frac{B-x}{C}}} \quad (2)$$

A: Asymptote

B: Inflection point

C: Inverse of slope

Logistic model growth rate

Derivative of the logistic model

$$\frac{dy}{dx} = \frac{A}{C} \frac{z}{(1+z)^2} , \quad z = e^{\frac{B-x}{C}}$$
 (3)

Derivative evaluated at x = B to obtain maximal growth rate (4) with standard deviation (5)

$$\left. \frac{dy}{dx} \right|_{x=B} = \frac{A}{4C} \tag{4}$$

$$\sigma_d = \frac{d}{4} \sqrt{\left(\frac{\sigma_A}{A}\right)^2 + \left(\frac{\sigma_C}{C}\right)^2} \tag{5}$$

Models - Dealing with noise

Additive noise

$$y \sim \mathcal{N}\left(\hat{y}, \, \sigma^2\right) \tag{6}$$

Multiplicative noise

$$\log\left(y\right) \sim \mathcal{N}\left(\log\left(\hat{y}\right), \, \sigma^2\right) \tag{7}$$

Models - Dealing with groupings

Complete Pooling

$$\hat{y}_i = \frac{A}{1 + e^{\frac{B - x}{C}}} \tag{8}$$

Mixed Effects Model, MEM (Partial Pooling)


$$\hat{y}_{ij} = \frac{(A+a_j)}{\frac{\left(B+b_j\right)-x}{\left(C+c_j\right)}}$$

$$1 + e^{\frac{\left(B+b_j\right)-x}{\left(C+c_j\right)}}$$
(9)

$$a_{j} \sim \mathcal{N}\left(0, \sigma_{a}^{2}\right) \quad b_{j} \sim \mathcal{N}\left(0, \sigma_{b}^{2}\right)$$
 $c_{j} \sim \mathcal{N}\left(0, \sigma_{c}^{2}\right)$


Models - Dealing with groupings


Multilevel mixed effects model



ECs dataset: Model fits


The MEM allows for variability between replicates






ECs dataset: Model selection


The MEM has **lower** information criteria values than the CP model







ECs dataset: Growth with ECs

No significant difference found at the 0.05 significance level







MS dataset: Multilevel MEM fit



MS dataset: Model selection


The multilevel MEM allows for relatively **good generalisation** and has **lower information criteria values**






MS dataset: Comparing growth rates

Maximal growth rate of *A. fumigatus* is **significantly larger** than all other species and strains





Discussion

- Maximal growth rate of A. fumigatus is higher than A. tubingensis and A. niger
 - Supports the hypothesis that the maximal growth rate is a virulence factor indicative of prevalence in IA
- Richard et al. (2018): ECs inhibit A. fumigatus conidia germination
 - Lack of significance obtained suggests that ECs only inhibit conidia germination but not hyphal growth
- Criticism of the logistic growth model unable to sufficiently model the lag phase
 - Baranyi et al. [9]
 - Mavridou et al. [10]

Thank you! Q&A

Appendix A - ECs dataset: Model fits




Figure 1: Fits of the additive noise CP and MEM models for A. fumigatus growth (a) with ECs and (b) without ECs

Appendix B - ECs dataset: Model selection




Figure 2: (a) Information criteria values and (b) Cross validation errors for the CP and MEM additive noise models

Appendix C - Multilevel mixed effects model

Appendix D - Model proposed by Baranyi et al. [9]

$$y(t) = y_0 + g A_n(t) - \frac{1}{m} \ln \left(1 + \frac{e^{mg A_n(t)} - 1}{e^{m(y_{max} - y_0)}} \right)$$
(10)
$$A_n(t) = \int_0^t \frac{s^n}{\lambda^n + s^n} ds$$

y: hyphal length

 y_0 : hyphal length at time t = 0

y_{max}: maximum hyphal length

m: Richard's curvature parameter after the exponential phase

n: curvature parameter after the lag phase

g: maximum hyphal growth rate

 λ : duration of lag phase

s: integral variable

Appendix E - Model proposed by Mavridou et al. [10]

$$y(t) = \begin{cases} y_0 & 0 \le t < \tau \\ (y_0 + v(t - \tau))e^{-\lambda(t - \tau)} & t \ge \tau \end{cases}$$
 (11)

y: hyphal length

 y_0 : hyphal length at the lag phase

au: duration of lag phase

v: growth rate

 λ : growth decay constant

References I



David W. Denning. "Therapeutic outcome in invasive aspergillosis". In: *Clinical Infectious Diseases* 23.3 (1996), pp. 608–615. ISSN: 10584838. DOI: 10.1093/clinids/23.3.608.



P. Bulpa, A. Dive and Y. Sibille. "Invasive pulmonary aspergillosis in patients with chronic obstructive pulmonary disease". In: *European Respiratory Journal* 30.4 (2007), pp. 782–800. ISSN: 09031936. DOI: 10.1183/09031936.00062206.



Brahm H. Segal and Thomas J. Walsh. "Current approaches to diagnosis and treatment of invasive aspergillosis". In: *American Journal of Respiratory and Critical Care Medicine* 173.7 (2006), pp. 707–717. ISSN: 1073449X. DOI: 10.1164/rccm.200505-727S0.



Thomas F. Patterson et al. "Invasive Aspergillosis Disease Spectrum, Treatment Practices, and Outcomes". In: *Medicine* 79.4 (July 2000), pp. 250–260. ISSN: 0025-7974. DOI: 10.1097/00005792-200007000-00006. URL: http://journals.lww.com/00005792-200007000-00006.

References II



Célimène Galiger et al. "Assessment of efficacy of antifungals against Aspergillus fumigatus: Value of real-time bioluminescence imaging". In: *Antimicrobial Agents and Chemotherapy* 57.7 (2013), pp. 3046–3059. ISSN: 00664804. DOI: 10.1128/AAC.01660-12.



Georg Maschmeyer, Antje Haas and Oliver A. Cornely. "Invasive aspergillosis: Epidemiology, diagnosis and management in immunocompromised patients". In: *Drugs* 67.11 (2007), pp. 1567–1601. ISSN: 00126667. DOI: 10.2165/00003495-200767110-00004.



Ricardo Araujo and Acacio Gonçalves Rodrigues. "Variability of germinative potential among pathogenic species of Aspergillus". In: *Journal of Clinical Microbiology* 42.9 (2004), pp. 4335–4337. ISSN: 00951137. DOI: 10.1128/JCM.42.9.4335–4337.2004.



Derek Paisley, Geoffrey D. Robson and David W. Denning. "Correlation between in vitro growth rate and in vivo virulence in Aspergillus fumigatus". In: *Medical Mycology* 43.5 (2005), pp. 397–401. ISSN: 13693786. DOI: 10.1080/13693780400005866.

References III



József Baranyi and Terry A. Roberts. "A dynamic approach to predicting bacterial growth in food". In: *International Journal of Food Microbiology* 23.3-4 (1994), pp. 277–294. ISSN: 01681605. DOI: 10.1016/0168-1605(94)90157-0.



Eleftheria Mavridou et al. "Composite Survival Index to Compare Virulence Changes in Azole-Resistant Aspergillus fumigatus Clinical Isolates". In: *PLoS ONE* 8.8 (2013), pp. 1–11. ISSN: 19326203. DOI: 10.1371/journal.pone.0072280.